HEALTHWPLG LOCAL 10 MIAMI
FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
The FDA approved Merck's Lipfendra, the first non-injectable pill targeting the PCSK9 protein to significantly reduce LDL cholesterol in high-risk patients. The drug offers a new option for those who need additional cholesterol-lowering beyond statins, with studies showing over 55% reductions in LDL levels.
Mentioned
Related Signal
Adjacent reporting
- FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
- FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
- FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
- FDA nod to Merck’s cholesterol pill opens a new frontier in cardiovascular care